The pure progesterone receptor (PR) antagonist onapristone enhances the anti-proliferative effects of CDK4/6 inhibitors and fulvestrant, a SERD, in preclinical in-vitro breast cancer models

Publications

Dec 7

Written by Martin Lehr

SABCS2018_Apristor_Cdk4-6 Combo_Poster.png

Context Therapeutics Announces New Preclinical Data on Apristor at San Antonio Breast Cancer Symposium

Context Announces Presentation of New Preclinical Data on Apristor in Combination with a Cdk4/6 Inhibitor at San Antonio Breast Cancer Symposium